Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03618407
Other study ID # HuKe
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2018
Est. completion date December 1, 2019

Study information

Verified date July 2018
Source Renmin Hospital of Wuhan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study mainly focused on the effect of early antiviral treatment on the duration of cough in influenza patients.investigators conducted an early investigation of patients with positive influenza virus and asked whether patients used antiviral drugs in the early stages. According to the use of drugs, patients were divided into oral oseltamivir group, oral lotus phlegm group and other groups, and investigators will collected Inspection information and medication status,during the treatment period of patients.


Description:

Cough is a common symptom of respiratory diseases and helps to clear respiratory secretions and harmful factors, but frequent severe coughing has a serious impact on the patient's work, life and social activities. Upper respiratory tract viral infection is a common cause of coughing. Many patients have a long duration of cough after suffering from flu. Cough can last for several weeks, and most often have irritating dry cough or a small amount of white mucus sputum. This type of cough is also often referred to as "subacute cough" or "post-infection cough." The mechanisms that cause this cough have not been fully elucidated, and the effect of conventional treatment is not good, and chest imaging has no obvious abnormalities. The use of large amounts of antibiotics is ineffective or ineffective. Antihistamine H1 receptor antagonists and central antitussives are often only effective or ineffective in the short term. The effects of various bronchodilators and even hormone drugs are not clear. Due to the poor efficacy of multiple treatments, patients are repeatedly subjected to various tests, which not only increases the pain but also aggravates the economic burden.

Therefore, it is necessary to further clarify the causes and treatment measures of post-influenza cough patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date December 1, 2019
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

For patients with flu-free flu, cough for at least one week.

1. In line with the flu etiological diagnostic criteria: According to the guidelines set by the National Health and Health Committee, the diagnosis is based on etiological screening methods or confirmed methods; ages 18 to 70 years.

2. There are no influenza complications such as acute lower respiratory tract infection, tonsillitis, sinusitis, otitis media, myocarditis, etc.

3. It is usually healthy and there are no chronic underlying diseases such as hypertension and diabetes.

4. Treating with cough as the main symptom, the cough lasts for at least one week and the chest radiograph is normal.

5. Signed informed consent.

Exclusion Criteria:

1. Suspected flu patients who have not received the flu etiology test;

2. There is a clear comorbid disease (combined with other sites of acute bacterial or viral infections);

3. There is a clear cough caused by other reasons;

4. With severe liver and kidney dysfunction;

5. Pregnant women.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Renmin Hospital of Wuhan University Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Renmin Hospital of Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cough duration Investigators will follow up every other week for follow-up calls or outpatients to ask about cough and medication, until the patient stops coughing, cough lasts from 1 day to 12 weeks, and cough time is greater than 12 weeks. Investigators should seriously exclude cough caused by other factors. No other factors are still included in the study, and the maximum time is no more than 6 months. If there are other factors causing cough, it will not be included in the study. 6 months
See also
  Status Clinical Trial Phase
Completed NCT00981513 - Direct and Indirect Benefits of Influenza Vaccination in Schools and Households Phase 4
Completed NCT00792051 - Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children N/A
Completed NCT04008823 - Study of Influenza Virus Infection in Children Hospitalized in Spain in Two Consecutive Influenza Seasons
Completed NCT02114255 - Effects of BCG on Influenza Induced Immune Response Phase 2/Phase 3
Completed NCT04706468 - To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection Phase 2